A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a special thanks to all of the patients who participated in the clinical trials. This is how #sciencemovesforward! 🍾businesswire.com/news/home/2…

This morning, we reported Q4 & full-year 2024 financial results & key updates. Join our LIVE webcast TODAY at 8:30 am ET or catch the replay later: bit.ly/374c75E Read the full press release: bit.ly/3QfavyS #RNAi #siRNA

So proud to be a part of the development of this content series about #mRNA! Tune in to learn more about how Moderna is changing the future of medicine

Our Dr. Jeffrey Weber spoke with the @WSJ about the promising melanoma research he presented at #AACR23 today. An #mRNA shot & pembro helped prevent relapse in hi-risk patients @moderna_tx @Merck wsj.com/articles/moderna-sho…

The first study in today’s press conference is presented by Jeffrey Weber, MD, PhD, from NYU Langone Perlmutter Cancer Center, and Ryan Sullivan, MD, from Mass General Cancer Center and Harvard Medical School. #AACR23 bit.ly/3mAi2NL

RT @moderna_tx: Today, Moderna and Merck announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201…

RT @moderna_tx: Today we announced that Phase 2 data on mRNA-4156/V940, our investigational personalized #mRNA #cancer vaccine, will be pre…

RT @moderna_tx: The last few years have amplified the responsibility of both private and public sectors to address health inequities that w…

RT @moderna_tx: Jordan has Glycogen Storage Disease Type 1a (GSD-1a) - which is a rare inherited metabolic disease that affects just 1 in 1…

RT @moderna_tx: On @rarediseaseday, Kyle Holen, MD, our SVP and Head of Development, Therapeutics and Oncology shares his motivation and co…

RT @moderna_tx: One medicine, for one patient. We, along with our partner @Merck, are pioneering a new frontier in the fight against #cance…

10 million people around the world die from cancer each year. For many years, @moderna_tx has pursued the pioneering use of MRNA in treating cancer — today’s news represents a big leap forward in that effort. investors.modernatx.com/news…

RT @moderna_tx: Stéphane Bancel, our Chief Executive Officer, speaks about mRNA-4157/V940, our investigational personalized #mRNA #cancer #…

The 1st randomized trial of an mRNA cancer vaccine to show efficacy: Stage III/IV melanoma, a combination immunotherapy + vaccine was superior to immunotherapy alone for recurrence-free survival. 157 participants (Phase 2b) w/ large trial planned PR by Moderna & Merck this AM

RT @moderna_tx: Today, we are highlighting progress on our environmental, social and governance (#ESG) strategy at our first ESG Day. Read…

RT @moderna_tx: Thank you @BillieJeanKing for connecting with some of our employees ahead of today’s women’s singles final at the #USOpen20…

The greatest to ever do it. Thank you, @serenawilliams ❤️

RT @moderna_tx: ANNOUNCEMENT 📢: We have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for our…

Known globally for its COVID-19 vaccine, Moderna is focused on educating the public on the broader promise of mRNA science, and on changing the future of medicine. I’m honored to be highlighted as a #changemaker in a new video. Learn more: aboutmRNA.com.

RT @moderna_tx: Welcome to the #mRNAge. At Moderna, we’re using our mRNA platform to develop new vaccines and therapeutics that may one day…